All patients had been treated with bortezomib and at least one IMiD, 3 (9%) had previously received carfilzomib, 59% had MM refractory to a PI, 75% had MM refractory to an IMiD and 66% had MM refractory to anti-CD38 monoclonal antibody (mAb). Here, CD38 is linked to Miyoshi myopathy.